It is the most common form of cancer among men, including in
The non-invasive diagnostic company Minomic claims its test is more effective than existing tests. The Australian company's MiStat test screens a urine or blood sample for a different protein only found on prostate cancer cells, while the current tests measure the blood level of PSA (Prostate Specific Antigen), a protein that is produced by the prostate gland.
With the ability to identify and test reliably for biomarkers of diseases such as cancer and diabetes, Minomic is in a niche and growing market with few rivals. The technology has major opportunities for rapid product range extension in diseases where traditional tests are limited or inadequate.
Proteomics is revolutionising protein molecular diagnostics through the discovery of protein biomarkers and panels of biomarkers that may be developed into highly predictive diagnostic tests. These tests will provide improved patient care as well as providing pharmacoproteomic services that lead to improved drug toxicology, efficacy and theranostic assays.
Minomic chief executive Dr
"The key difference (between the MiStat test and PSA tests) is its specificity, so it (the MiStat test) is better at picking false positives from true positives than the PSA tests," Dr Walsh said.
Minomic hopes to put the test before the
The company is also looking for suitable US partners to further its research activities.
Most Popular Stories
- 15 Myths That Could Ruin Your Hispanic Ad Campaign
- Bitcoin Clones Lurch Onto Financial Scene
- General Motors Names Mary Barra as First Female CEO
- AIG to Create 230 Jobs in Charlotte
- Clinton to Keynote Annual Simmons Leadership Conference
- How Bitcoin and Other Cryptocurrencies Work
- Californians Want to Legalize Marijuana
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia
- Selena Gomez, Shakira Among Top Hispanic Searches
- Budget Deal Sets Off Grumbles in Both Houses